Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy

Conditions

• Basal-Like Breast Carcinoma
• BRCA1 Mutation Carrier
• BRCA2 Mutation Carrier
• Breast Carcinoma
• Estrogen Receptor Negative
• HER2/Neu Negative
• Hereditary Breast and Ovarian Cancer Syndrome
• Ovarian Carcinoma
• Pancreatic Carcinoma
• Progesterone Receptor Negative
• Prostate Carcinoma
• Recurrent Breast Carcinoma
• Recurrent Fallopian Tube Carcinoma
• Recurrent Ovarian Carcinoma
• Recurrent Primary Peritoneal Carcinoma
• Solid Neoplasm
• Triple-Negative Breast Carcinoma

Interventions

• OTHER: Laboratory Biomarker Analysis
• OTHER: Pharmacological Study
• DRUG: Veliparib

Sponsor

National Cancer Institute (NCI)